Age: 56.0
Sex: M
Vaccine: COVID19
Symptoms: Blood uric acid, COVID-19, SARS-CoV-2 test
Clinical narrative: Tested Covid + by home Ag test 5/8/22; confirmed by PCR on 5/9/22. Mild symptoms (sore throat, nasal congestion) started 5/7/22. Treatment with Paxlovid 5/8-5/12/22. Tested negative by home Ag test on 5/12/22. On 5/19/22 developed nasal congestion an; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (Tested Covid + by home Ag test 5/8/22; confirmed by PCR on 5/9/22. Mild symptoms (sore throat, nasal congestion) started 5/7/22. Treatment with Paxlovid 5/8-5/12/22. Tested negative by home Ag test on 5/12/22. On 5/19/22 developed nasal congestion an) in a 56-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Obesity and Allergic reaction to bee sting (Bees allergy). Concomitant products included ALLOPURINOL and ACETYLSALICYLIC ACID (BABY ASPIRIN) for an unknown indication.    On 01-May-2022, the patient received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-May-2022, the patient experienced COVID-19 (Tested Covid + by home Ag test 5/8/22; confirmed by PCR on 5/9/22. Mild symptoms (sore throat, nasal congestion) started 5/7/22. Treatment with Paxlovid 5/8-5/12/22. Tested negative by home Ag test on 5/12/22. On 5/19/22 developed nasal congestion an). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 08-May-2022 to 12-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (Tested Covid + by home Ag test 5/8/22; confirmed by PCR on 5/9/22. Mild symptoms (sore throat, nasal congestion) started 5/7/22. Treatment with Paxlovid 5/8-5/12/22. Tested negative by home Ag test on 5/12/22. On 5/19/22 developed nasal congestion an) had resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 08-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On 09-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On 12-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On 19-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On 20-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On 21-May-2022, SARS-CoV-2 test: positive (Positive) Positive. On 22-May-2022, SARS-CoV-2 test: negative (Negative) Negative. On an unknown date, Blood uric acid: high (High) elevated uric acid.         It was reported that patient had mild symptoms of sore throat, nasal congestion which had started on 7-May-2022 and was treated with Paxlovid. on 19-May-2022, patient again developed nasal congestion and these nasal symptoms continued until 22-May-2022. No additional treatment was recieved by the patient.  Company Comment:  This is a spontaneous case concerning a 56-year-old male patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19, which occurred 8 days after receiving a dose of mRNA-1273 as the fourth dose of COVID-19 vaccine (no information disclosed on previous COVID-19 vaccinations). Initially, patient experienced mild symptoms of sore throat and nasal congestion then tested positive for COVID-19 antigen test on the next day and was also confirmed by COVID-19 RT-PCR test. Patient was given a five-day-course of Paxlovid treatment and tested negative for COVID-19 after the treatment course. However, seven days after the treatment with Paxlovid, patient developed nasal congestion then tested positive thrice for COVID-19. No additional treatment was given to the patient. Three days after, symptoms were resolved and patient was tested negative for COVID-19. The benefit-risk relationship of mRNA-1273 is not affected by this report.; Sender's Comments: This is a spontaneous case concerning a 56-year-old male patient with no relevant medical history reported, who experienced the unexpected non-serious adverse event of special interest COVID-19, which occurred 8 days after receiving a dose of mRNA-1273 as the fourth dose of COVID-19 vaccine (no information disclosed on previous COVID-19 vaccinations). Initially, patient experienced mild symptoms of sore throat and nasal congestion then tested positive for COVID-19 antigen test on the next day and was also confirmed by COVID-19 RT-PCR test. Patient was given a five-day-course of Paxlovid treatment and tested negative for COVID-19 after the treatment course. However, seven days after the treatment with Paxlovid, patient developed nasal congestion then tested positive thrice for COVID-19. No additional treatment was given to the patient. Three days after, symptoms were resolved and patient was tested negative for COVID-19. The benefit-risk relationship of mRNA-1273 is not affected by this report.